A phase 1, Multicenter, Open-label, Dose-escalation and expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical activity study of orally administered AG-881 in patients with advanced solid tumors, Including Gliomas, With an IDH1 and/or IDH2 mutation. Here, IDH1 is linked to central nervous system cancer.